Genmab AS (WBO:GMAB) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:GMAB Genmab AS WBO:GMAB
97 GF Score
Price €268.80
GF Value €305.15
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS  (WBO:GMAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab AS Cyclically Adjusted PB Ratio Related Terms


Genmab AS Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted PB Ratio Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.49 17.79 10.22 5.69 6.34

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.50 6.27 6.34 5.12 0.00

WBO:GMAB vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


WBO:GMAB
97GF Score
Genmab AS WBO:GMAB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=83.789/122.9700*122.9700
=83.789

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 8.771 100.200 10.764
201612 10.746 100.300 13.175
201703 11.089 101.200 13.474
201706 12.205 101.200 14.831
201709 11.889 101.800 14.361
201712 13.982 101.300 16.973
201803 14.295 101.700 17.285
201806 14.871 102.300 17.876
201809 15.396 102.400 18.489
201812 17.598 102.100 21.195
201903 17.578 102.900 21.006
201906 18.159 102.900 21.701
201909 25.622 102.900 30.619
201912 29.201 102.900 34.896
202003 29.585 103.300 35.218
202006 36.727 103.200 43.763
202009 37.858 103.500 44.980
202012 39.714 103.400 47.230
202103 40.691 104.300 47.975
202106 40.993 105.000 48.009
202109 43.168 105.800 50.174
202112 45.504 106.600 52.492
202203 47.093 109.900 52.694
202206 49.452 113.600 53.531
202209 54.057 116.400 57.108
202212 56.703 115.900 60.162
202303 56.996 117.300 59.751
202306 59.327 116.400 62.676
202309 63.213 117.400 66.212
202312 65.789 116.700 69.324
202403 66.391 118.400 68.954
202406 65.075 118.500 67.530
202409 67.827 118.900 70.149
202412 77.209 118.900 79.852
202503 77.338 120.200 79.120
202506 74.742 120.700 76.148
202509 79.586 121.600 80.483
202512 81.062 121.200 82.246
202603 80.059 121.680 80.908
202606 83.789 122.970 83.789

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Genmab AS (WBO:GMAB) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €268.80 is trading 11.9% below its estimated GF Value™ of €305.15. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for WBO:GMAB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €305.15 vs. price of €268.80 (11.9% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the WBO:GMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score

Get the complete analysis for WBO:GMAB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€268.80
Price
€305.15
GF Value